- Report
- April 2025
- 175 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- April 2025
- 250 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- June 2025
- 564 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 276 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 413 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 150 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 181 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 142 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 79 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 193 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 146 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 456 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 182 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 287 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- August 2024
- 140 Pages
Global
From €2686EUR$2,999USD£2,290GBP
- Report
- June 2025
- 193 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- May 2025
- 134 Pages
Global
From €2686EUR$2,999USD£2,290GBP
- Report
- December 2024
- 200 Pages
Global
From €3359EUR$3,750USD£2,863GBP
- Report
- May 2025
- 150 Pages
Global
From €2417EUR$2,699USD£2,061GBP
- Report
- May 2025
- 150 Pages
Global
From €2417EUR$2,699USD£2,061GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more